ASCO 2024 – Scemblix could set new standard in front-line leukaemia
But will the FDA accept the surrogate endpoint used in ASC4First?
ASCO 2024 preview – conjugates in focus
This weekend’s oncology conference will feature at least 30 different ADC projects.
ASCO 2024 preview – with more patients Merus claims better efficacy
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
ASCO 2024 abstract movers – Merus convinces, at first
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
ASCO 2024 preview – waiting for Blueprint and Caribou
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
ASCO 2024 preview – new Car-T target shows liver cancer promise
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
ASCO 2024 preview – toxicity looms large for J&J
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
